This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Congestive heart failure
  • /
  • Levosimendan in pulmonary hypertension and right h...

Levosimendan in pulmonary hypertension and right heart failure

Read time: 1 mins
Published:6th Jul 2018
Author: Hansen MS, Andersen A, Nielsen-Kudsk JE.
Availability: Free full text
Ref.:Pulm Circ. 2018;8(3):2045894018790905

Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle. Levosimendan is a calcium sensitizing agent with inotropic, pulmonary vasodilatory, and cardioprotective properties. Given its pharmacodynamic profile, levosimendan could be a potential novel agent for the treatment of right ventricular failure caused by pulmonary hypertension. The aim of this review is to provide an overview of the current knowledge on the effects of levosimendan in pulmonary hypertension and right heart failure.


Read abstract on library site

Access full article